Contact Us
  • Choose License Type

Obesity is defined by excessive body fat and higher body mass index. The average BMI index for obesity is above 30 (obese). Obesity is one of the most prevalent disease conditions across the world, and it is prevalent in developed, emerging, and undeveloped regions. Surgeries that aid in the treatment of obesity include, gastric bypass, adjustable gastric banding, gastric sleeve, duodenal switch, and intragastric balloon treatment.

Statistics:

The global obesity management drugs market is estimated to account for US$ 764.7 Mn in terms of value in 2020 and is expected to reach US$ 1,078.9 Mn by the end of 2027.

Global Obesity Management Market: Drivers

R&D of new products is expected to propel growth of the global obesity management market over the forecast period. For instance, in May 2019, VIVUS, Inc., a biopharmaceutical company, announced the commencement of phase IV safety and efficacy Qsymia for weight management in obese patients.

Global Obesity Management Market: Opportunities

Adoption of novel technologies in treatment of obesity is expected to offer lucrative growth opportunities for players in the global obesity management market. For instance, in August 2020, researchers from Harvard University reported use of CRISPR-Cas9 gene-editing technology to engineer human white fat so that it displays the properties of brown fat.

Global Obesity Management Market: Restraints

Side effects and safety controversies is expected to hinder growth of the global obesity management market. Though the number of obesity drug users are rapidly increasing due to their many benefits, studies show that there are certain side effects and adverse health effects of obesity drugs over long term that include, high cholesterol, diabetes, high blood pressure, heart diseases, strokes, sleep apnea, depression, asthma, and cancer.

Key Takeaways:

The global obesity management drugs market was valued at US$ 729.9 Mn in 2019 and is forecast to reach a value of US$ 1,078.9 Mn by 2027 at a CAGR of 5.0% between 2020 and 2027. Major factor driving the growth of global obesity management drugs market during the forecast period include increasing prevalence of obesity, and number of products available.

Orlistat held dominant position in the global obesity management drugs market in 2019, accounting for 31.9% share in terms of value, followed by Liraglutide and Lorcaserin, respectively.

Market Trends

Major players in the global obesity management market are focused on adopting collaboration and partnership strategies to expand their product portfolio. For instance, on June 2019, NovoFit, a global distributor for fitness equipment, entered a strategic partnership with Amer Sports’ leading fitness brand, Precor for product distributorship in Australia. The partnership is projected to increase market positioning of NovaFit and Amer Sports in Australia.

Possible link of obesity with cancer is expected to propel growth of the global obesity management market. For instance, in September 2020, a research at Washington University School of Medicine in the U.S. reported that for every 5kg of weight gained the risk of the cancer increases by 5%.

To know the latest trends and insights related to global myopia and presbyopia treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/anti-obesity-drugs-market-2824

Regulations

U.S

  • The 505(b)(2) regulation offers a less expensive and faster new drug development pathway. 505 (b)(2) was added to FD&C act by Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman act).
  • When the generic company files ANDA with Paragraph IV certification, the first applicant to submit substantially completed ANDA is given 180 days market exclusivity under para IV of Hatch-Waxman act
  • In October 1999, U. S. Department of Health and Human Services Food and Drug Administration published a draft guidance for applications covered by section 505 (b)(2)

Global Obesity Management Market: Competitive Landscape   

Major players operating in the global obesity management market include, F Hoffmann La Roche Ltd., GlaxoSmithKline plc., Orexigen Therapeutics, Inc., Arena Pharmaceuticals, Inc., VIVUS, Inc., Novo Nordisk A/S, and Eisai Co., Ltd.

Global Obesity Management Market: Key Developments

Major players in the global obesity management market are focused on adopting collaboration and partnership strategies to expand their product portfolio. For instance, in July 2018, Eisai Co., Ltd. entered an agreement to grant exclusive development and marketing rights to CY Biotech for its anti-obesity agent lorcaserin hydrochloride (lorcaserin) in China.

Segmentation

  • By Drug Type
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • By Distribution Channel
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • By Region
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner